Richard Philbrook
Principal ScientistCuraleafRichard Philbrook is a cannabis industry executive and entrepreneur best known as the founder and former CEO of Dark Heart Cannabis. Under his leadership, the company became a leading provider of premium cannabis genetics and nursery services in California, recognized for its innovation, quality, and commitment to regulatory compliance. Philbrook guided Dark Heart through significant growth and its eventual acquisition by Curaleaf, where he continued to contribute his expertise in cultivation, genetics, and large-scale operations. He is widely regarded as a thought leader in cannabis agriculture and supply chain development, advocating for sustainable practices and the advancement of the regulated cannabis industry.
Genetics as Strategy: Continuous Optimization for Commercial Cannabis Cultivation
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling to source, trial, and scale genetics that buyers already expect. That lag costs margin, shelf space
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling to source, trial, and scale genetics that buyers already expect. That lag costs margin, shelf space, and competitive position.
This session shows commercial growers how to flip that script. You'll learn how leading operators replace reactive trend-chasing with a structured genetic program built
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling to source, trial, and scale genetics that buyers already expect. That lag costs margin, shelf space, and competitive position.
This session shows commercial growers how to flip that script. You'll learn how leading operators replace reactive trend-chasing with a structured genetic program built on continuous sourcing, trialing, and evaluation. We'll connect each decision to commercial viability, so genetics become a strategic asset rather than a guessing game.
